Where is Aclipse Therapeutics headquartered?

Aclaris Therapeutics is recorded with headquarters in Radnor Township, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Aclipse Therapeutics publicly traded?

Yes — Aclipse Therapeutics is listed as a public company with ticker ACRS on NYSE in SEC EDGAR-derived records.

What drugs are associated with Aclipse Therapeutics?

We link 1 drug profile(s) where Aclipse Therapeutics appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Aclipse Therapeutics sponsoring?

Aclipse Therapeutics is linked to 33 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Aclipse Therapeutics as applicant?

18 USPTO PatentsView record(s) name Aclaris Therapeutics or a normalized variant as applicant.

What pipeline phases does Aclipse Therapeutics have in our database?

Phase distribution from linked programs: phase 2: 25, phase 1: 3, phase 3: 3, approved: 2.

How many US-approved drugs are linked to Aclipse Therapeutics?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Where does NovaPharmaNews source data on Aclipse Therapeutics?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Aclipse Therapeutics data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Aclipse Therapeutics data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Aclaris Therapeutics Pharmaceuticals Company Profile

Name: Aclaris Therapeutics intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 170 N Radnor Chester Rd, Radnor Township, Pennsylvania, US
Founded: 2012
Employees: 10
Programs: 33
Drugs: 12
Patents: 18

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Aclipse Therapeutics is a pharma organization headquartered in Radnor Township, USA. It trades on NYSE under ticker ACRS. Primary therapeutic focus areas include Atopic Dermatitis, Seborrheic Keratosis, Common Wart, Alopecia Areata, Rheumatoid Arthritis. NovaPharmaNews links 33 clinical program(s), 1 drug profile(s), and 18 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (25), phase 1 (3), phase 3 (3).

Company snapshot

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.

1 approved product(s) across US/EU regulatory metadata.
33 active pipeline program(s) linked via ClinicalTrials.gov.
18 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Aclaris Therapeutics. Not investment advice.

Top assets

View drugs (12) View projects (33)

Lead pipeline drugs

abaloparatide
approved
dose
Marketed / approved
emulsifying ointment (for use only as a base combined with active ingredients)
Marketed / approved
estradiol
approved

Active clinical programs

A-101 Common Wart
Phase 3
A-101 Solution Seborrheic Keratosis
Phase 3
Active Common Wart
Phase 3
A-101 Seborrheic Keratosis
Phase 2

Momentum

Proprietary activity score for Aclaris Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 36 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Lakefront Biotherapeutics NV

TA overlap score 39.8
Peer + 0 momentum

Nektar Therapeutics UK

TA overlap score 31.4
Peer + 0 momentum

Coherus Oncology

TA overlap score 25
Peer + 0 momentum

Verrica Pharmaceuticals

TA overlap score 21.4
Peer + 0 momentum

Forteo

TA overlap score 21

Recent activity

Latest pipeline, patent, and corporate events for Aclaris Therapeutics.

Jun 8, 2026 Clinical update
ATI-052-ASTH-101 — Phase 1
Jun 8, 2026 Clinical update
ATI 502 0.46% Topical Solution — Phase 2
Jun 8, 2026 Clinical update
Active — Phase 3
Jun 5, 2026 Clinical update
ATI-045, Placebo to ATI-045 — Phase 2
Jun 5, 2026 Clinical update
ATI-501 400mg BID (Low dose) — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Aclaris Therapeutics?

Aclipse Therapeutics is a pharma organization headquartered in Radnor Township, USA. It trades on NYSE under ticker ACRS. Primary therapeutic focus areas include Atopic Dermatitis, Seborrheic Keratosis, Common Wart, Alopecia Areata, Rheumatoid Arthritis. NovaPharmaNews links 33 c
Is Aclaris Therapeutics publicly traded?

Yes. Aclaris Therapeutics is listed with ticker ACRS on NYSE per SEC EDGAR records linked on this profile.
What drugs does Aclaris Therapeutics develop or market?

We link 12 drug profile(s) where Aclaris Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/aclaris-therapeutics#company-drugs.
What are the latest developments for Aclaris Therapeutics?

In the last 12 months our linked public records show 33 trial program update(s) and 2 US patent grant(s) tied to this profile.
What therapeutic areas does Aclaris Therapeutics focus on?

Aclaris Therapeutics focuses on Atopic Dermatitis, Seborrheic Keratosis, Common Wart based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Immunology

Oncology

Rare Disease